Germany’s cartel authority has approved a deal with Denmark’s Novo Nordisk to buy Cardior Pharmaceuticals, the regulator said in a statement on Thursday. The acquisition of Hannover-based Cardior Pharmaceuticals for 1.03 billion euros ($1.1 billion) comes as Novo works to expand its focus on diabetes and weight-loss methods to include cardiovascular treatments.